Related Experiment Video
Updated: Aug 16, 2025
Induction of Invasive Transitional Cell Bladder Carcinoma in Immune Intact Human MUC1 Transgenic Mice: A Model for Immunotherapy Development
Published on: October 30, 2013
Novel Therapies for High-Risk Non-Muscle Invasive Bladder Cancer
Bashir Al Hussein Al Awamlh1, Sam S Chang2,3
1Department of Urology, Vanderbilt University Medical Center, A-1302 Medical Center Drive, Nashville, TN, 37232, USA. Bashir.alhussein@vumc.org.
Purpose Of Review:
The treatment options for high-risk non-muscle invasive bladder cancer (NMIBC), particularly following BCG, remain limited. We highlight recent, promising therapies for high-risk NMIBC.
Recent Findings:
Several therapies utilizing different mechanisms of action have demonstrated favorable results in the BCG-naïve and BCG-unresponsive settings. These treatments include intravenous and intravesical immunotherapy, viral- and bacterial-based intravesical therapies, combination intravesical chemotherapy regimens, and novel intravesical chemotherapy administration. Overall, the efficacy and tolerability of emerging treatments for NMIBC appear promising and provide potential alternatives to radical cystectomy. As the landscape of managing BCG-unresponsive disease evolves, clinical trials will explore future options and determine effective alternatives.
Insights
Treatment options for high-risk non-muscle invasive bladder cancer (NMIBC) after BCG are limited. Recent therapies show promise as alternatives to radical cystectomy, offering new hope for patients with BCG-unresponsive disease.
Area of Science:
- Uro-oncology
- Cancer treatment innovation
Background:
- High-risk non-muscle invasive bladder cancer (NMIBC) presents limited treatment options, especially after Bacillus Calmette-Guérin (BCG) therapy.
- Effective management strategies for BCG-refractory NMIBC are urgently needed.
Purpose of the Study:
- To review recent advancements in therapeutic options for high-risk NMIBC.
- To highlight emerging treatments for patients with non-muscle invasive bladder cancer who have not responded to BCG.
Main Methods:
- Review of recent clinical findings and emerging therapies for high-risk NMIBC.
- Analysis of novel immunotherapy, intravesical therapies, and combination chemotherapy regimens.
Main Results:
- Several novel therapies demonstrate favorable outcomes in both BCG-naïve and BCG-unresponsive NMIBC settings.
- Intravenous and intravesical immunotherapies, viral/bacterial-based intravesical treatments, and novel chemotherapy administration show promise.
- Emerging treatments exhibit promising efficacy and tolerability, offering alternatives to radical cystectomy.
Conclusions:
- Promising new therapeutic avenues are available for high-risk NMIBC, particularly for BCG-unresponsive cases.
- These novel treatments may provide viable alternatives to cystectomy, improving patient outcomes.
- Ongoing clinical trials will further define the role of these therapies in managing advanced NMIBC.
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against...
02:56Treatment Resistant Cancers
01:27Tumor Immunotherapy
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:50Combination Therapies and Personalized Medicine
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...